Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | The immunotherapy NSCLC revolution

Solange Peters • 30 Sep 2019
ESMO 2019
Lung Cancer Non-Small Cell Lung Cancer

Solange Peters, MD, PhD, University Hospital Vaudois, Lausanne, Switzerland, discusses how immunotherapies are a revolution for the treatment of non-small cell lung cancer (NSCLC), and the issue of their accessibility. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Solange Peters

2:01
Unanswered questions on immunotherapy for lung cancer
Solange Peters • 11 Sep 2022
3:09
ESMO 2022: Highlights from the Presidential Symposium
Solange Peters • 11 Sep 2022
3:18
Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumab
Solange Peters • 11 Sep 2022
2:42
Aligning the educational resources put out by ESMO
Solange Peters • 30 Sep 2019

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals